Delgocitinib: all 26 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Topical JAK-Inhibition of Early-Stage CTCLNot yet recruitingNCT07781449Phase 2
• Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)Not yet recruitingNCT07671157Phase 2
• Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen PlanopilarisRecruitingNCT07487948Phase 2
• A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen SclerosusRecruitingNCT07335588Phase 3
• The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and ItchNot yet recruitingNCT07203274Not applicable
• A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar PustulosisRecruitingNCT07013201Phase 2
• Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand EczemaCompletedNCT05355818Phase 3Results posted
• A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing AlopeciaCompletedNCT05332366Phase 2Results posted
• A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand EczemaCompletedNCT05259722Phase 3Results posted
• Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 TrialsCompletedNCT04949841Phase 3Results posted
• Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)CompletedNCT04872101Phase 3Results posted
• Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand EczemaCompletedNCT04871711Phase 3Results posted
• Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.TerminatedNCT03958955Phase 2Results posted
• Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.CompletedNCT03725722Phase 2Results posted
• Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand EczemaCompletedNCT03683719Phase 2Results posted
• LEO 124249 Ointment in the Treatment of Alopecia AreataCompletedNCT02561585Phase 2Results posted
• Topical Delgocitinib for Facial VitiligoActive, not recruitingNCT07820098Phase 2
• A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand EczemaCompletedNCT06004050Phase 3
• Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand EczemaCompletedNCT05486117Phase 1
• A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy PeopleCompletedNCT05050279Early Phase 1
• Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib CreamCompletedNCT04807751Phase 1
• Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib CreamCompletedNCT04361136Phase 1
• Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and ChildrenCompletedNCT03826901Phase 1
• Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.TerminatedNCT03325296Phase 2
• Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse PsoriasisCompletedNCT02695940Phase 2
• Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand EczemaCompletedNCT02664805Phase 2

← Delgocitinib overview